TY - CHAP
T1 - Personalized radiation therapy (PRT) for lung cancer
AU - Jin, Jian Yue
AU - Kong, Feng Ming (Spring)
N1 - Publisher Copyright:
© Springer International Publishing Switzerland 2016.
PY - 2016/10/1
Y1 - 2016/10/1
N2 - This chapter reviews and discusses approaches and strategies of personalized radiation therapy (PRT) for lung cancers at four different levels: (1) clinically established PRT based on a patient’s histology, stage, tumor volume and tumor locations; (2) personalized adaptive radiation therapy (RT) based on image response during treatment; (3) PRT based on biomarkers; (4) personalized fractionation schedule. The current RT practice for lung cancer is partially individualized according to tumor histology, stage, size/location, and combination with use of systemic therapy. During-RT PET-CT image guided adaptive treatment is being tested in a multicenter trial. Treatment response detected by the during-RT images may also provide a strategy to further personalize the remaining treatment. Research on biomarker-guided PRT is ongoing. The biomarkers include genomics, proteomics, microRNA, cytokines, metabolomics from tumor and blood samples, and radiomics from PET, CT, SPECT images. Finally, RT fractionation schedule may also be personalized to each individual patient to maximize therapeutic gain. Future PRT should be based on comprehensive considerations of knowledge acquired from all these levels, as well as consideration of the societal value such as cost and effectiveness.
AB - This chapter reviews and discusses approaches and strategies of personalized radiation therapy (PRT) for lung cancers at four different levels: (1) clinically established PRT based on a patient’s histology, stage, tumor volume and tumor locations; (2) personalized adaptive radiation therapy (RT) based on image response during treatment; (3) PRT based on biomarkers; (4) personalized fractionation schedule. The current RT practice for lung cancer is partially individualized according to tumor histology, stage, size/location, and combination with use of systemic therapy. During-RT PET-CT image guided adaptive treatment is being tested in a multicenter trial. Treatment response detected by the during-RT images may also provide a strategy to further personalize the remaining treatment. Research on biomarker-guided PRT is ongoing. The biomarkers include genomics, proteomics, microRNA, cytokines, metabolomics from tumor and blood samples, and radiomics from PET, CT, SPECT images. Finally, RT fractionation schedule may also be personalized to each individual patient to maximize therapeutic gain. Future PRT should be based on comprehensive considerations of knowledge acquired from all these levels, as well as consideration of the societal value such as cost and effectiveness.
KW - Adaptive radiation therapy
KW - Biomarkers
KW - Lung cancer
KW - Personalized radiation therapy
KW - Radiomics
UR - http://www.scopus.com/inward/record.url?scp=84951875229&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84951875229&partnerID=8YFLogxK
U2 - 10.1007/978-3-319-24932-2_10
DO - 10.1007/978-3-319-24932-2_10
M3 - Chapter
C2 - 26703805
AN - SCOPUS:84951875229
T3 - Advances in Experimental Medicine and Biology
SP - 175
EP - 202
BT - Advances in Experimental Medicine and Biology
PB - Springer New York LLC
ER -